NASDAQ:PLSE Pulse Biosciences (PLSE) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free PLSE Stock Alerts $8.63 +0.23 (+2.74%) (As of 01:14 PM ET) Add Compare Share Share Today's Range$8.58▼$9.0950-Day Range$7.80▼$10.8852-Week Range$2.36▼$13.62Volume66,113 shsAverage Volume174,524 shsMarket Capitalization$475.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pulse Biosciences alerts: Email Address Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About Pulse Biosciences Stock (NASDAQ:PLSE)Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.Read More PLSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLSE Stock News HeadlinesMarch 21, 2024 | americanbankingnews.comPulse Biosciences (PLSE) to Release Earnings on ThursdayMarch 17, 2024 | finance.yahoo.comPLSE Apr 2024 25.000 callMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 17, 2024 | finance.yahoo.comPLSE Oct 2024 17.500 callMarch 16, 2024 | finance.yahoo.comPLSE Oct 2024 12.500 callMarch 16, 2024 | finance.yahoo.comPLSE Jul 2024 2.500 putMarch 14, 2024 | businesswire.comPulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024March 13, 2024 | msn.comPulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearanceMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 10, 2024 | investing.comFDA clears Pulse Biosciences' soft tissue ablation systemMarch 9, 2024 | markets.businessinsider.comPulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode SystemMarch 8, 2024 | stockhouse.comPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode SystemMarch 8, 2024 | businesswire.comPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode SystemFebruary 14, 2024 | markets.businessinsider.comPulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock UpFebruary 14, 2024 | finance.yahoo.comPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyFebruary 14, 2024 | businesswire.comPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyFebruary 2, 2024 | finance.yahoo.comCompanies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In GrowthJanuary 31, 2024 | finance.yahoo.comPulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF SymposiumJanuary 6, 2024 | finance.yahoo.comInsiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchasesJanuary 2, 2024 | finance.yahoo.comPulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac ClampDecember 20, 2023 | finance.yahoo.comPulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac CatheterDecember 5, 2023 | msn.comPulse Biosciences director Duggan buys shares worth $1.4M - filingDecember 3, 2023 | finance.yahoo.comExecutive Chairman of Pulse Biosciences Robert Duggan Buys More StockNovember 27, 2023 | marketwatch.comPulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by DugganNovember 27, 2023 | msn.comPulse Biosciences as chairman cleared to buy up to 1M stockNovember 21, 2023 | seekingalpha.comPulse Biosciences: Cash Flow Bleed Remains A Concern Ahead Of 2024 CatalystsNovember 21, 2023 | markets.businessinsider.comPulse Biosciences Files 510(k) Submission With FDA For Its CellFX NsPFASee More Headlines Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/30/2023Today3/28/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PLSE CUSIPN/A CIK1625101 Webwww.pulsebiosciences.com Phone(510) 906-4600FaxN/AEmployees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-154.33% Return on Assets-53.29% Debt Debt-to-Equity RatioN/A Current Ratio9.50 Quick Ratio9.50 Sales & Book Value Annual Sales$700,000.00 Price / Sales660.96 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-140.00Miscellaneous Outstanding Shares55,080,000Free Float16,690,000Market Cap$462.67 million OptionableOptionable Beta1.69 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Executive Chairman Mr. Kevin P. Danahy (Age 53)President & CEO Comp: $393.25kMr. Darrin R. Uecker (Age 58)CTO & Director Comp: $487.24kMr. Mitchell E. Levinson (Age 64)Chief Strategy Officer Comp: $361.34kDr. Richard Nuccitelli Ph.D.Chief Science OfficerMr. Kenneth B. Stratton Esq. (Age 55)J.D., General Counsel & Corporate Secretary Ms. Patty PerlaVice President of Human ResourcesMr. David DanitzSenior Vice President of EngineeringDr. Gansevoort Dunnington M.D.Chief Medical OfficerDr. Niv Ad M.D.Chief Science Officer of Cardiac SurgeryMore ExecutivesKey CompetitorsOraSure TechnologiesNASDAQ:OSURNevroNYSE:NVROAVITA MedicalNASDAQ:RCELBioventusNYSE:BVSSurmodicsNASDAQ:SRDXView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 19,789 shares on 3/22/2024Ownership: 0.036%Vanguard Group Inc.Bought 316,519 shares on 3/11/2024Ownership: 1.195%Nuveen Asset Management LLCBought 3,607 shares on 2/15/2024Ownership: 0.048%Barclays PLCBought 19,187 shares on 2/15/2024Ownership: 0.040%Citadel Advisors LLCBought 9,900 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PLSE Stock Analysis - Frequently Asked Questions How have PLSE shares performed in 2024? Pulse Biosciences' stock was trading at $12.24 at the start of the year. Since then, PLSE shares have decreased by 26.9% and is now trading at $8.95. View the best growth stocks for 2024 here. When is Pulse Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our PLSE earnings forecast. How can I listen to Pulse Biosciences' earnings call? Pulse Biosciences will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences, Inc. (NASDAQ:PLSE) released its quarterly earnings results on Thursday, March, 30th. The company reported ($0.24) EPS for the quarter. The firm had revenue of ($0.01) million for the quarter. What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO? 2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX). When did Pulse Biosciences IPO? Pulse Biosciences (PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO. Who are Pulse Biosciences' major shareholders? Pulse Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.19%), Vanguard Group Inc. (1.19%), Griffin Asset Management Inc. (0.47%), Northern Trust Corp (0.33%), Westside Investment Management Inc. (0.06%) and Nuveen Asset Management LLC (0.05%). Insiders that own company stock include Kevin Patrick Danahy, Mitchell E Levinson and Robert W Duggan. View institutional ownership trends. How do I buy shares of Pulse Biosciences? Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLSE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.